Abstract Purpose: We evaluated the safety, maximum tolerated dose, pharmacokinetics, and biological effects of the combination of the Raf-1, RET, KIT, platelet-derived growth factor receptor, and vascular endothelial growth factor receptor 2 kinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib. Experimental Design: A standard 3 + 3 phase I dose-escalation design was used with a 28-day cycle (sorafenib daily and tipifarnib for 21 days, by mouth). Results: Fifty patients were treated; 43 reached restaging evaluation after cycle 2. The most common side effects were grade 1 to 2 rash, hyperglycemia, and diarrhea. Doselimiting toxicity was rash, and the recommended phase II dose is sorafenib 400 mg p.o. qam/200 mg p.o. qpm and tipifarnib p.o. 100 mg bd. Despite the low doses of tipifarnib, one quarter of patients had ≥50% reduction in farnesyltransferase levels. Interestingly, six of eight patients with medullary thyroid cancer had durable stable disease (n = 3) or partial remissions (n = 3), lasting 12 to 26+ months. Five of the six responders had available tissue, and RET gene mutations were identified in them. Prolonged (≥6 months) stable disease was also seen in nine patients as follows: papillary thyroid cancer (n = 4; 18+ to 27+ months), adrenocortical cancer (n = 2; 7 and 11 months), and one each of melanoma (platelet-derived growth factor receptor mutation positive; 14 months), renal (6 months), and pancreatic cancer (6 months). Conclusions: Our study shows that the combination of tipifarnib and sorafenib is well tolerated. Activity was seen, especially in patients with medullary thyroid cancer, a tumor characterized by RET mutations. (Clin Cancer Res 2009;15(22):7061-8) 
limiting step in its posttranslational modification and is required for its oncogenic activity (1, 11, 12) .
The development of farnesyltransferase and Raf kinase inhibitors such as tipifarnib and sorafenib, respectively, provides a unique opportunity to test the hypothesis that, by combining these agents, a synergistic or additive effect on the Ras/Raf/ MAP/ERK kinase/ERK and related pathways might be achieved clinically in advanced cancer. As a first step, we report a phase I study on the combination that describes its safety, toxicities, maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamic effects, and preliminary indications of efficacy.
Patients, Materials, and Methods
Patient eligibility and selection. Inclusion criteria include ≥18 y; histologically confirmed advanced cancer with ≤4 previous cytotoxic chemotherapies or no standard therapy that could increase survival by 3 mo; Eastern Cooperative Oncology Group performance status of ≤2; Response Evaluation Criteria in Solid Tumors (RECIST; ref. 13) measurable disease on which biopsy can be done, although biopsies were optional; leukocytes (≥3,000/μL); absolute neutrophil count (≥1,500/μL); platelets (≥1,000,000/μL); total bilirubin (≤1.5); aspartate aminotransferase/alanine aminotransferase ≤2.5 times the upper limit of normal; creatinine within the upper limit of normal (≥60 m/L/min/ 1.73 m 2 for patients with creatinine levels above the upper limit of normal); and discontinuation of therapies ≥4 wk before study entry.
Exclusion criteria include continuing grade 3 adverse events resulting from therapy administered ≥4 wk earlier; central nervous system metastases, except patients having previous radiation; allergies to imidazoles or compounds similar to sorafenib or tipifarnib; uncontrolled hypertension (systolic pressure, >140 mm Hg; diastolic, >90 mm Hg); current bleeding diathesis; ≥grade 2 peripheral neuropathy; uncontrolled intercurrent illness; New York Heart Association classification of >2; impaired swallowing; therapeutic anticoagulation; human immunodeficiency virus positive; pregnancy; and childbearing potential individuals unwilling to use adequate contraception.
Study design. The Division of Cancer Treatment and Diagnosis of the National Cancer Institute supplied sorafenib (BAY43-9006; Nexavar) and tipifarnib (Zarnestra; R115777).
All patients signed a written informed consent meeting M.D. Anderson Cancer Center Institutional Review Board policy and National Cancer Institute requirements. A standard 3 + 3 dose-escalation design was used (Table 1) . Each cycle consisted of 28 d of sorafenib and 21 d of tipifarnib (3 wk on and 1 wk off per 28-d cycle). Toxicity was graded according to the Cancer Therapy Evaluation Program Common Toxicity Criteria, version 3.0. Dose-limiting toxicity (DLT) was defined as any grade 4 hematologic toxicity delaying the next course for over 2 wk, accompanied by a lasting infection or bleeding requiring hospitalization. A clinically significant nonhematologic DLT was defined as ≥grade 3 adverse event possibly attributable to drug. Exceptions were alopecia, insomnia, weight gain, amenorrhea, and galatactorrhea. Grading for nausea, vomiting, and diarrhea was based upon toxicity, despite maximal symptomatic treatment. The DLT window encompassed the first 28 d of treatment. The MTD was defined as dose level in which ≤1 of 6 patients experienced a DLT.
Baseline evaluations were conducted within 1 wk before protocol start. Physical exams were conducted every 3 wk, with weekly hematologic/biochemical laboratories. Scans were required within 4 wk before therapy. RECIST response evaluation occurred every 8 wk, and evidence of a partial or complete response was confirmed within 4 wk.
Patients continued on treatment until disease progression, unacceptable adverse events, intercurrent illness preventing further administration, or patient withdrawal. Dose reduction occurred if grade 2 to 3 nonhematologic adverse events were observed despite symptomatic treatment, excluding nonclinically significant metabolic or laboratory abnormalities.
Translational Relevance
We believe the findings in this phase I combination study represent an important contribution to the phase I, combination-targeted therapy and thyroid cancer literature. We have reported here the safety, pharmacokinetic, pharmacodynamics, responses, and maximum tolerated dose of the unique combination of sorafenib, a mulitkinase inhibitor (Raf, RET), and the farnesyletranseferase (Ras) inhibitor.
Our data support that this combination is well tolerated and has shown significant activity in thyroid malignancies, particularly medullary thyroid cancer patients with RET kinase mutations. This is the first report of significant responses of medullary thyroid cancer with targeted therapies such as sorafenib and tipifarnib. Moreover, the unique combination adds to the growing body of literature of the tolerability, toxicities, and activity of these rationally targeted combinations. Laboratory correlative studies Farnesyltransferase enzyme analysis in peripheral blood mononuclear cells. Blood samples (30 mL in EDTA tubes) were drawn within 2 wk before starting the drug combination and during day 21 of cycle 1. Peripheral blood mononuclear cells were snap frozen at -80°C until analysis for farnesyltransferase activity, using previously described methods (14, 15) . The farnesyltransferase value for the pretreatment sample (baseline) was set at 100%, and the farnesyltransferase activity on day 21 was presented as a percentage of the baseline.
Pharmacokinetics. Plasma drug levels were assessed during course 1 (weeks 1, 2, 3). Plasma samples (5 mL) from 24 patients were obtained: immediately before the combination, at 30 min and 2, 4, 6, and 24 h (before the following second daily dose). Plasma was removed, frozen, and stored at -80°C until analysis.
Levels of tipifarnib were assessed using a validated high performance liquid chromatography-UV method. Plasma was alkalinized with NaOH (0.01 mol/L) and then extracted with heptane:isoamyl alcohol (v/v, 90:10). An internal standard (R121550) was used to correct for extraction efficiency. The chromatographic peaks of both tipifarnib and R121550 were detected at 240 nm. Based on quality control samples assayed along with patient samples, intraday and interday precision ranged from 3.9% to 11.2%, and accuracy ranged from 92.0% to 1.5.5%. Identity of peaks measured as tipifarnib was confirmed by liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/ MS). Analysis of sample content of sorafenib was determined by a validated LC/MS/MS assay with a lower limit of quantitation of 1 ng/mL. Based on quality control samples, intraday and interday precision ranged from 2.4% to 14.3%, and accuracy ranged from 89.8% to 111.5%. Tolfonate (Sigma Chemical) was used as an internal standard. Following protein precipitation, drug and internal standard were extracted with diethyl ether, which was then dried under N 2; residue was reconstituted in MeOH before analyses.
RET, KIT, and PDGFR sequencing. Hereditary medullary thyroid cancer patients have germline RET mutations, and a subset of patients with sporadic medullary thyroid cancer also harbor RET mutations in tumor. To test for these mutations, DNA was extracted from paraffinembedded tumor using the DNeasy Tissue kit (Qiagen). PCR was done to amplify exons 10, 11, 13, 14, 15, and 16 of the RET gene. Similarly, exons 9, 11, 13, and 17 of the KIT gene and exons 12 and 18 of the PDGFR gene (16) were examined in a melanoma patient with prolonged stable disease. PCR was done using LA-Taq (TaKaRa) and was carried out in a PTC-100 thermocycler (MJ Research). After the Exonuclease I-Shrimp Alkaline Phosphatase purifying method (Roche), the products were directly sequenced in an ABI PRISM 3730 Genetic Analyzer (Applied Biosystems). Mutations were cross-referenced with the Human Gene Mutation Database, 11 Entrez SNP, 12 and PubMed. Table 2 ). Forty-three patients reached their first restaging evaluation. Seven patients came off study early because of toxicities (rash, n = 2; elevated lipase, n = 2) or comorbidities unrelated to drug (atrial fibrillation, n = 1; secondary malignancy, n = 1; thrombus, n = 1) necessitating early withdrawal.
Dose escalation and MTD. No patients received therapy at dose levels -1 or 5 ( Table 1 ). The initial protocol started at dose level 6 (sorafenib 400 mg bd; tipifarnib 100 mg bd), but two of six patients developed a grade 3 maculopapular erythematous rash requiring hospitalization, and dosing was modified. Five were treated at new dose level 1 (sorafenib 400 mg qd; tipifarnib 100 mg qd), with one patient coming off early after discovery of a second malignancy (gastric cancer) and a second for early progression. Four were treated at dose level 2, with one coming off before completion of the DLT window because of progression. Three were treated at dose level 3, with one patient developing a grade 3 rash. Therefore, an additional three were enrolled with no further DLTs. At dose level 4, two of four patients developed a grade 3 rash; therefore, the MTD was defined as dose level 3 (sorafenib 400 mg qam, 200 mg qpm; tipifarnib 100 mg bd). An additional 25 patients were treated at the MTD to further delineate the pharmacokinetics, pharmacodynamics, and activity.
Safety. The most common toxicities for all cycles were grade Pharmacology. Plasma levels of tipifarnib and sorafenib were assessed during course 1 (weeks 1, 2, 3; Fig. 1 ). Complete plasma sample collections were obtained from 24 patients. Plasma levels of tipifarnib (100 mg bd) reached equilibrium within 6 hours and were maintained at ∼100 ng/mL during the 21-day treatment cycle (Fig. 1B) . In contrast, steady-state plasma levels of sorafenib were reached after 7 days, with only slight additional accumulation (Fig. 1A) . Neither the frequency of sorafenib nor its dose had an apparent effect on tipifarnib plasma levels or vice versa. Plasma levels of sorafenib (2.5-4 μg/mL) were similar to those reported (17) . Tipifarnib steady-state levels, however, averaged 100 ng/mL and were lower than those previously reported, but the small number of patients in previous reports at a 100-mg bd dose level precluded determining whether these differences were significant (18, 19) .
Analysis of patient peripheral blood mononuclear cells for farnesyltransferase activity. Of 50 enrolled patients, 31 had matching basal and on-study peripheral blood mononuclear cell samples, which were analyzed for farnesyltransferase activity, summarized as percentage of baseline activity of farnesyltransferase (Table 4 ). All patients, except for patient 24 (200 mg bd) received 100 mg bd of tipifarnib. There was no correlation between the dose of sorafenib administered and inhibition of farnesyltransferase activity.
Farnesyltransferase activity showed less inhibition than previous reports even after taking tipifarnib for 3 weeks, probably because of the low doses of tipifarnib (14, 15) , but despite the low dose, 8 of 31 analyzable samples showed inhibited farnesyltransferase activity of ≥50%. Three patients had increased farnesyltransferase activation on day 21 of cycle 1 (187%, 209.3%, and 532%) compared with basal farnesyltransferase activity.
Tumor responses. Overall, 43 of 50 patients reached first restaging; the other seven came off early because of toxicities (n = 4) or unrelated comorbidities (n = 3). Twenty (47%) of the 43 patients who reached their first restaging had progression as their best response.
Twelve of 15 patients with thyroid cancer enrolled reached first restaging. Figure 2A depicts their best response. Three of the six patients with medullary thyroid cancer who reached first restaging had a partial response, lasting 14, 16+, and 26+ months, whereas three had minor regressions (stable disease) lasting 12 to 16 months. None of the six had a family history of multiple endocrine neoplasia Type 2 (MEN2) or familial thyroid cancer. RET mutation analysis from tumor was positive in all five for Abbreviations: AST, aspartate aminotransferase; ALT, alanine aminotransferase; Sq., squamous.
whom tissue was available (see RET mutation analysis). All six patients also had marked reductions in calcitonin, and five of the six had a decrease in carcinoembryonic antigen (Fig. 2B) . All four patients with papillary thyroid cancer who reached a first restaging had durable tumor regressions (16-20%) lasting 18+, 19+, 20, and 27+ months. The patient with follicular thyroid cancer had short-lived tumor stability (4 months) and the patient with anaplastic thyroid cancer showed rapid tumor progression (1 month).
Ten additional patients had stable disease for 4 to 14 months. These patients included three of the seven patients with melanoma (4, 4, and 14 months), both patients with adrenocortical cancer (7 and 11 months), two of three patients with renal cancer (5 and 6 months), one of four patients with pancreatic cancer (6 months), one of six patients with breast cancer (5 months), and one of three patients with colorectal cancer (4 months). Of interest, the patient with melanoma who remained stable for 14 months showed a mutation of PDGFR-α but not of KIT. The tumor was found to have a heterozygous mutation (GTC to CTC at codon 824) that resulted in an amino acid substitution from valine to leucine. This mutation was not evident in normal tissue sequenced from the same patient.
In addition, we reviewed the history of our thyroid cancer patients, including assessment of their scans immediately before treatment. Because patients had a variety of treatments immediately before tipifarnib and sorafenib, including radioactive iodine, surgery, and systemic agents, and their scans were done over a variety of intervals. Over a median of 3 months (range, 2-5 months), the patients with thyroid cancer (excluding anaplastic cancer) showed a median of 39% (range, 14-110%) increase in disease by RECIST. This reflects the fact that patients with the most aggressive disease were generally referred to the phase I clinic.
RET mutational analysis. All five of the patients with medullary thyroid cancer who reached their first restaging and who had available blood had no identifiable germline RET mutation in blood as per standard screening for MEN2/familial medullary thyroid carcinoma and no family history of MEN2/familial medullary thyroid carcinoma ( Fig. 2A) . One patient declined testing and had no family history of MEN2/familial medullary thyroid carcinoma. All five patients who reached first restaging and who had available paraffin tissue had an exon 11 RET mutation ( Fig. 2A) . Of interest, one patient had a novel RET mutation of exon 11, a 6-bp deletion (TGTGCG) seen as double peaks after codon 628. This deletion alters leucine, cysteine, and aspartic acid at codons 629 to 631 and has been previously reported by us (20) . All the mutations are located in the extracellular cysteine-rich domain, which can cause ligand independent homodimerization and RET kinase constitutive activation.
Discussion
This phase I study on combined sorafenib and tipifarnib showed safety and excellent tolerance, albeit with each drug given at lower doses than the individual recommended doses. The recommended phase II dose for the combination is sorafenib 400 qam/200 mg qpm and tipifarnib 100 mg bd. For the most part, toxicities of the combination were similar to those seen with tipifarnib and sorafenib as single agents and mainly included diarrhea and rash. Rash was the DLT, and this was not surprising, given that rash develops in a significant minority of patients treated with either sorafenib or tipifarnib. Of note, 46% of patients developed grade 1 to 2 hyperglycemia (nonfasting), which is high relative to what might be expected from either agent alone (3, 21, 22) . The reason for the hyperglycemia is unclear, but it has recently been shown that side-effect similarities may point to unexpected drug targets (23) . It is therefore conceivable that the hyperglycemia reflects an off-target effect on a signal such as mammalian target of rapamycin (mTOR), given that mTOR inhibitors result in frequent hyperglycemia (24) . One patient developed multiple squamous cell skin cancers within 3 months of starting treatment (25) . The treatment was stopped, and the tumors were excised and did not recur. This effect is most likely due to sorafenib because it has been reported with this agent (26) .
Our pharmacokinetic studies showed that steady-state plasma levels of sorafenib are similar to those reported elsewhere (17) . Steady-state levels of tipifarnib are low, but the small number of patients treated at the 100 mg bd dose level in previous studies precludes a comparison (18, 19) . Of interest, despite the low doses of tipifarnib, 8 of 31 patients evaluated showed ≥50% inhibition of farnesyltransferase activity. Regardless, studies have shown that even these low doses of tipifarnib can induce responses, including complete remissions, in myelodysplastic syndrome or acute myelogenous leukemia patients (10, 14, 15) .
Recently, investigators have reported significant responses and increased median progression-free survival with sorafenib in patients with differentiated (papillary and follicular) thyroid cancers (27, 28) . Our study also shows significant activity for tipifarnib/ sorafenib in patients with papillary thyroid cancer, with all four treated showing regressions lasting 18+ to 27+ months. These patients had shown clear progression by RECIST (median progression, 39%) over a median of 3 months before starting the study. In addition, we report significant responses in patients with medullary thyroid cancer with all six patients who reached their first restaging, achieving prolonged stable disease or a partial response (duration, 12 to 26+ months; Fig. 2A) . In all cases, calcitonin dropped significantly, as did carcinoembryonic antigen in five of the patients (Fig. 2B) , with none showing any significant new side effects after long-term administration.
Medullary thyroid cancer can be hereditary or sporadic, with the molecular hallmark of the hereditary form being germline mutations in the RET kinase gene. A subset of patients with sporadic medullary thyroid cancer, especially those with more aggressive disease, will show mutations in RET kinase in their tumors (29) . In our study, of the five responders with medullary thyroid cancer who had paraffin tissue available for RET mutation analysis, each had an activating mutation. It is unclear if the activity of tipifarnib/sorafenib in medullary thyroid cancer was due entirely to the inhibition of RET by sorafenib because the RET kinase pathway is complex. Ligand activation of the RET kinase activates a cascade of signaling pathways, for example, Janus-activated kinase, mitogen-activated protein kinase, c-jun-NH 2 -kinase, Ras/Raf/mitogen-activated protein kinase, nuclear factor κ-light-chain-enhancer of activated B cells, and the phosphoinositide 3-kinase/AKT pathways (29) . Because farnesyltransferase inhibitors can also inhibit AKT and MAP/ERK kinase activation, it is possible but not known whether tipifarnib inhibited these pathways, thereby increasing the activity of sorafenib against RET. Moreover, it is conceivable that the suppression of VEGFR kinase by sorafenib also contributed to the medullary thyroid cancer responses. In conclusion, we show that combining sorafenib and tipifarnib is well tolerated at doses up to and including sorafenib 400 mg p.o. qam/200 mg p.o. qpm and tipifarnib 100 mg p. o. bd. The most clinically significant side effect was rash. Of interest, patients with medullary thyroid cancer bearing RET kinase mutations had durable partial responses (n = 3) or stable disease (n = 3), lasting 12 to 26+ months (20) , and four patients with papillary thyroid cancer have been stable for 18+ to 27+ months. Prolonged stable disease (14 months) was also seen in a patient with melanoma harboring a PDGFR-α mutation; responses to sorafenib have also been previously reported anecdotally in patients with melanoma bearing a KIT mutation (30) . In addition, ≥6 months stable disease was observed in patients with adrenocortical (7, 11 months), renal (6 months), and pancreatic cancer (6 months), suggesting that the activity and mechanism of action of tipifarnib/sorafenib in these malignancies warrants additional exploration (21) . Finally, larger studies are planned in patients with medullary thyroid cancer to better assess response rates and determine whether response is based on the activity of one drug, that is, sorafenib, or if the suppression of multiple pathways by combining the two drugs, contributed to the salutary effects seen. 2 . A, waterfall plot showing best response (by RECIST) of patients with thyroid cancer who reached their first restaging evaluation. All five of the medullary thyroid cancer patients with available paraffin blocks had RET kinase mutations of exon 11. These mutations locate in the extracellular cysteine-rich domain, which can cause ligand independent homodimerization and constitutive activation of the RET kinase. B, best percent change in calcitonin and carcinoembryonic antigen levels from baseline in the six patients with medullary thyroid cancer who reached their first restaging. All six patients had a rapid decline in their calcitonin levels, and all patients, except patient 2, had a significant decrease in carcinoembryonic antigen levels.
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